Loading
Total declarations
Companies
▲ Purchases (4 ops.)
▼ Sales (5 ops.)
Latest filing published 23 Oct 2025 for Summit Therapeutics Inc., €862k.
Filing timeline
BuySaleManmeet Singh Soni
Insider track record
Disclosed buys
4
Disclosed sells
5
Signal history
Closed purchases
Market purchases
4
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- +1061.4%Entry US$2.02 · Close at T+365 US$23.46
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Manmeet Singh Soni: trading record in brief
Manmeet Singh Soni, listed as finance chief, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Reata Pharmaceuticals Inc and Summit Therapeutics Inc. The record holds 17 filings, for trades running from 14 August 2020 to 21 October 2025.
Market trades split into 4 purchases (€5.4M) and 5 sales (€2.0M). The net balance comes to €3.4M on the buying side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 6 share grants.
A typical purchase (the median) is worth €270k.
Most recently, on 23 October 2025, the filings show a share grant worth €862k in Summit Therapeutics Inc. The clock since the last published purchase (16 October 2023) now reads 1,104 days. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Manmeet Singh Soni
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations17 total
53,361 shares@ US$18.7413.2% of flowCommon StockSEC:0001569769-25-000002:0
44,052 shares@ US$22.7013.9% of flowCommon StockSEC:0001599298-24-000136:0
2,976,190 shares@ US$1.6872.8% of flowCommon StockSEC:0001569769-23-000007:0
Canonical exit: 11 Jan 2024 (T+90)
62,621 sharesClass A common stockSEC:0000899243-23-019540:0
1,755 shares@ US$168.413511.4% of flowClass A common stockSEC:0001209191-23-046306:0
75,000 sharesClass A common stockSEC:0001209191-23-044009:0
6,000 shares0Class A common stockSEC:0001209191-23-041931:0
4,711 shares@ US$99.617318.2% of flowClass A common stockSEC:0001209191-23-037043:0
12,440 shares@ US$84.320140.4% of flowClass A common stockSEC:0001209191-23-030223:0
50,000 shares0Class A common stockSEC:0001209191-23-028269:0
622 shares@ US$84.6952.1% of flowClass A common stockSEC:0001209191-23-017235:0
3,587 shares@ US$87.9712.5% of flowClass A common stockSEC:0001209191-23-016339:0
23,513 shares0Class A common stockSEC:0001209191-23-001143:0
50,000 shares0Class A common stockSEC:0001209191-22-001633:0
16,000 shares@ US$26.222815.5% of flowClass A common stockSEC:0001209191-22-000391:0
Canonical exit: 31 Mar 2022 (T+90)
2,000 shares@ US$100.22Class A common stockSEC:0001209191-20-046765:0
Canonical exit: 12 Nov 2020 (T+90)
1,000 shares@ US$100.19Class A common stockSEC:0001209191-20-046765:1
Canonical exit: 12 Nov 2020 (T+90)
17 of 17 declarations
